Organ system for circulating blood in animals
POPULARITY
Categories
Cardiovascular disease is the No. 1 killer of women nationwide, yet during midlife—the crucial time for prevention—many women fall out of regular medical care.Host Dr. Rachel Pope is joined by Dr. Lisa Larkin, an internal medicine and women's health expert and founder of Ms. Medicine. They discuss why women's cardiovascular risk spikes around menopause and what you can do about it now.The Midlife Risk SpikeDr. Larkin highlights a failure in the healthcare system: women aged 40 to 60 often receive the least medical care, right when prevention is most critical.The perimenopausal transition causes rapid and significant metabolic changes: Cholesterol rises and HDL protection declines. Development of insulin resistance. Increase in visceral fat (the "risky fat" around organs), which is a marker for cardiovascular disease.Standard risk tools often underestimate risk in women because they don't account for sex-specific factors like adverse pregnancy outcomes (preeclampsia, gestational diabetes). Women are also often allowed to run higher blood pressures, missing opportunities for early intervention.Management & The "Missed Boat" QuestionDr. Larkin stresses that Body Composition is more important than BMI, as most women gain risky visceral fat during this time. She recommends tracking body composition annually.For women in their mid-60s who ask if they've missed the boat on prevention or Hormone Therapy (HT): Assessment is Key: Dr. Larkin performs a highly individualized assessment, often utilizing a Coronary Calcium Score to check for established plaque. If Risk is Low: A patient with perfect health metrics and a Calcium Score of zero may still be a candidate for HT to treat symptoms and support bone health. If Risk is High: The priority is to aggressively fix every single risk factor (hypertension, elevated lipids) before considering hormones, as established plaque may carry more risk with estrogen.Dr. Larkin emphasizes that women must be their best advocates because the healthcare system is currently failing to provide the comprehensive care needed during this pivotal stage of life.
This week we speak with Ohio State ACHD fellow Andrew Freddo MD, PhD about a recent large single center study he conducted assessing the cardiovascular drugs that adult Fontan patients are taking and whether they might offer us insights into general well-being. Are there agents that are associated with worse outcomes? If so, is this a situation of the agent causing harm or is it a possible marker of illness? Are there agents associated with improved outcomes? These are amongst the questions reviewed with Dr. Freddo this week. DOI: 10.1016/j.jacadv.2025.102070
New Zealand has the third highest adult obesity rate in the OECD, and the rates are going up. One in three adult New Zealanders is classified as obese, and one in 10 children. Even if you take into account, yes, yes, yes, a lot of the All Blacks front row are considered obese if you use the BMI. And yes, you might have a slow metabolism or it's your hormones and there's nothing you can do about it, that's still a lot of fat people and a lot of associated health issues. The cost of obesity in this country is estimated as being between four and nine billion dollars per year. It's a huge range, four to nine billion, but it's where you classify the different illnesses, and it depends on which survey you look at. Even if you go at the lower limit, $4 billion is a hell of a lot of money to spend on something that doesn't need to happen. Cardiovascular disease alone costs more than three billion. The human misery too that comes with being obese for many kids and adults is another intangible cost. But now we have a drug for that. GLP-1 is the magic ingredient. It regulates blood sugar levels and slows down the rate at which food leaves the stomach, thus making people fuller for longer. And apparently, according to those who've used it, it turns off the chatter in your head, the constant thinking about food. Well, if I have this and then I walk for an hour and then I'll be able to have something else. Ooh. Ooh, I'm not hungry now, but ooh, imagine what I could have for dinner. Planning the next meal before you've actually finished the one in front of you. It's that constant food chatter. I think Oprah was the first one to talk about it, how she never realised until she took the magic drug, that you didn't have to listen to that noise in your head, that other people didn't have it. So the GLP-1-mimicking drugs seem to be a powerful tool. They're actually effective. And after decades of research and money being poured into weight loss drugs, this one seems to work. More importantly, this one doesn't have the side effects of the speed drugs that were given out in the 70s as diet pills. It was basically methamphetamine. Some people are losing around 15% of their body weight or more after just over a year on the semaglutide. Wegovy became available to New Zealanders in July. It's not publicly funded. It's a weekly drug and comes at an ongoing cost of about $500 a month. Should it be funded? David Seymour, the Associate Minister for Health, seems to think so. In the past he said, well, if you spend a buck to save five, why wouldn't you? Although as he points out, Pharmac's decisions are independent of any ministers. The NHS in Britain has done the sums. If the weight loss drugs were prescribed to everyone who needed them according to the stringent criteria, the prohibitively expensive cost would bankrupt the NHS even after taking into account the cost of the health problems that they would inevitably solve. So you would have to do the sums for this country to work out whether it would pay off in the long run. If that's what it does, if, you know, one buck is going to save us five long term. If a huge cohort, in every sense of the word, of New Zealanders is going to live a better life, a healthier life as a result of the investment, surely it's worth it? But to get buy-in, you would have to get the support of the majority of New Zealanders. One in three adult New Zealanders is classified as obese, two in three aren't. And they might say, well, I'm doing everything right for my body. I'm doing the exercise and I'm not greedy. Some might well see obesity as a moral failing. Throughout history, it's been seen as a moral failing. One of the seven deadly sins is gluttony. In Dante's Inferno, the gluttons are consigned to the third circle of hell. Gluttons are people with uncontrolled appetites who worship food as a kind of God, according to Dante. Therefore, the gluttons' punishment in the third circle of hell, instead of eating fine delicate foods and wines, they're forced to eat filth and mud and be rained upon by foul smelling rain. Cerberus, the dog, ravages them and mauls them. It's a miserable punishment. Gluttons have always been seen as moral failures. Which may, I think, have been fair at a time where resources were scarce, and if you were wealthy, you got other people to get food for you and you ate it at the expense of the poor. But these days, when the food industry is making money out of processed food designed to hook you in and give you an insatiable appetite for more, I think we can take the moral failing out, can't we? Most people know what to do. There's far more to it than just calories in, calories out and more exercise, and even the makers of Wegovy and Ozempic and the like understand that too. They say it's not going to work on its own. It's the same with bariatric surgery, you have to do so much more than just stop the food going in. There is much, much more to it than that. If we do the sums, the NHS says they've done them and the cost is too high. But if we do the sums for this country, and ultimately, we spend a dollar to save five, why wouldn't we? Why wouldn't we put everybody who wants the Wegovy onto it? See omnystudio.com/listener for privacy information.
EP. 237 - Grab my FREE GUIDE: Assess Your Metabolic Health Today I'm covering one of my favorite topics: high blood pressure. I've yet to meet a case I couldn't help significantly course correct with lifestyle changes and a solid, integrative approach to care. This truly is not a drug deficiency problem. High blood pressure is a lifestyle issue, plain and simple, and a brand-new study from October 2025 drives that point home beautifully. In this episode, I'm breaking down that research, which looked at millions of people and found that almost every case of heart disease, stroke, or heart failure had at least one non-optimal risk factor in play. We'll talk about what those risk factors are, what they mean for you, and most importantly, what you can do about them. Topics Discussed: → What are the main causes of high blood pressure? → Can you lower blood pressure naturally without medication? → How does lifestyle affect cardiovascular health? → What are non-optimal risk factors for heart disease? → What is the naturopathic approach to hypertension? Sponsored By: → Cozy Earth | Black Friday has come early at https://CozyEarth.com! Right now, you can stack my code DRTYNA on top of their sitewide sale, giving you up to 40% off in savings. These deals won't last, so start your holiday shopping today! → Vandy | Ready to give Vandy a try? Go to https://vandycrisps.com/TYNA and use code TYNA for 25% off your first order. → Sundays | As a Listener of The Dr Tyna Show, you can Get 50% off your first order of Sundays. Go to https://sundaysfordogs.com/DRTYNA and use code DRTYNA at checkout. → BIOptimizers | For 15% off go to https://bioptimizers.com/drtyna and use promo code DRTYNA → Timeline | Go to https://timeline.com/DRTYNA and use code DRTYNA for 20% off → Paleo Valley | Head to https://paleovalley.com/drtyna to save 15% on your order today! On This Episode We Cover: → 00:00:00 - Introduction → 00:04:22 - Lifestyle & heart health → 00:06:05 - Key risk factors → 00:10:12 - Menopause & cholesterol → 00:16:20 - Optimize metabolism → 00:20:57 - Stress & cortisol → 00:26:29 - Brain health → 00:30:37 - Muscle mass → 00:32:10 - Sleep & hormones → 00:34:25 - Cardiovascular fitness → 00:36:57 - Relaxation techniques → 00:40:50 - Building community → 00:46:13 - Hydration tips Show Links: → Very High Prevalence of Nonoptimally Controlled Traditional Risk Factors at the Onset of Cardiovascular Disease → FREE GUIDE: Assess Your Metabolic Health → Metabolic Revamp Toolkit → AquaTru Water Filters: Use my affiliate link: https://aquatruwater.com/?oid2=50&affid2=2320&c=docereconsultinggroup to save on my favorite water filters. Discount applied at checkout. Black Friday Sale is on now. → Jaspr: https://jaspr.co/DRTYNA Further Listening: → Heart Health Playlist → Metabolic Health Playlist Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.
Cardiovascular-kidney-metabolic (CKM) syndrome is progressive, but can be halted or even reversed with effective management. Guests Chiai Ndumele, MD, PhD, and Joe Saseen, PharmD, BCPS, BCACP, describe the role of inflammation and how the biologic factors for diagnosis and treatment are nested within a patient's social context.2023 AHA Statement Cardiovascular-Kidney-Metabolic Health: https://www.ahajournals.org/doi/10.1161/cir.0000000000001184 Related Resources:PCNA CKM tools and resources: https://pcna.net/resources/patient-education/patient-information/cardiovascular-kidney-metabolic-syndrome-resources/ AHA Cardiovascular Kidney Metabolic Health Presidential Advisory: https://professional.heart.org/en/science-news/cardiovascular-kidney-metabolic-health-a-presidential-advisoryAHA CKM Syndrome Implementation Guide: https://www.heart.org/en/professional/cardiovascular-kidney-metabolic-health/implementationPCNA CKM Resource list: https://pcna.net/resources/patient-education/patient-information/cardiovascular-kidney-metabolic-syndrome-resources/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
The bidiretional relationship between cardiac and renal systems means that any dysfunction can cause a cascade of health issues. Learn about team-based care strategies for nurses and other professionals to monitor and manage patients with these conditions from guests Andrew Bzowyckyj, PharmD, BCPS, CDCES, FAPhA, FADCES, and Serina Gbaba, DNP, MBA, FNP-BC.PCNA CKM tools and resources: https://pcna.net/resources/patient-education/patient-information/cardiovascular-kidney-metabolic-syndrome-resources/ IPEC core competencies (Interprofessional Education Collaborative): https://www.ipecollaborative.org/ipec-core-competencies CVD in CKD: Pathophysiological Insights and Therapeutic Options: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.050686Social Determinants of CVD:https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.319811See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
* Add FAAN to Anita's creds after Oct. 18.Guests: Anita Rich, DNP, RN, CHFN, CDCES, FAAN, and Jane DeMeis.Related resources:PCNA CKM tools and resources: https://pcna.net/resources/patient-education/patient-information/cardiovascular-kidney-metabolic-syndrome-resources/ 2025 ACC Expert Consensus Statement on Medical Weight Mgmt for Optimization of CV Health: https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024 Adiponectin, Leptin and CV Disorders: (https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.314458Racial and Ethnic Disparities in Adult Obesity in the US: https://www.cdc.gov/pcd/issues/2019/18_0579.htmCardiometabolic Syndrome: A Global Health Issue: https://www.uspharmacist.com/article/cardiometabolic-syndrome-a-global-health-issueTaking Aim At Belly Fat: https://www.health.harvard.edu/newsletter_article/taking-aim-at-belly-fatGender Disparities in People Living with Obesity: https://pubmed.ncbi.nlm.nih.gov/34526743/ Systematic review and meta-analysis suggests obesity predicts onset of CKD: https://www.sciencedirect.com/science/article/pii/S0085253816307529AHA Weight-Loss Strategies for Prevention and Treatment of Hypertension: https://pubmed.ncbi.nlm.nih.gov/34538096/ Renal Fat Accumulation Assessed by MRI or CT and Metabolic Disorders: https://pmc.ncbi.nlm.nih.gov/articles/PMC12194363/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this week's JACC podcast, Editor-in-Chief Dr. Harlan Krumholz explores how context, precision, and physiology converge to shape modern cardiovascular care. He opens with an editorial on "The Geography Gap," challenging the one-size-fits-all approach to cardiovascular risk models that ignore geographic variation in disease outcomes. Other featured studies in this issue include trials (OCEAN Mitral, PULSE), optimizing outcomes after transcatheter mitral repair, plus uncovering genetic links between placental malperfusion and congenital heart disease, evaluating CT angiography follow-up after left main PCI, and refining emergency triage with high-sensitivity troponin testing. Dr. Krumholz also speaks to editorials in this issue providing insight on the accompanying JACC articles, and a HeartBeat submission, with a reflection on balance and compassion in pediatric cardiology. Finally, he touches on our other JACC journal content, including new findings on blood groups and COVID-19 cardiovascular outcomes, and the first JACC: Basic to Translational Science Editor's page from the new editor-in-chief, Matthias Nahrendorf, MD, PhD, on the evolving landscape of translational science. This week in JACC highlights cardiology's movement toward more localized, integrated, and human-centered precision medicine.
Dr Sharonne Hayes, Professor of cardiovascular medicine and founding director of Mayo Clinic women's heart clinic, and Dr. Marysia Tweet, Associate Professor of cardiovascular medicine, and co-leader of the Spontaneous Coronary Artery Dissection Registry and leader in women's heart health join the show for this amazing November chapter of Always on EM. They are world experts on Spontaneous Coronary Artery Dissection authoring over 60 peer reviewed articles on the topic and in this chapter we explore with them the pitfalls and pearls related to making this diagnosis in the ED. SCAD is an important cause of myocardial infarction especially in patients who would not otherwise seem to be at risk for heart attacks for example active young women without comorbidities, and its imperitive that we as emergency physicians are current on this diagnosis. DONATE TO DR JIM GREGOIRE SCHOLARSHIP FUND To honor the life of Dr. Jim Gregoire, dear friend of this show, consider donating to his scholarship fund. Go to https://give.mayoclinic.org/give/616870/#!/donation/checkout Go to: What would you like your donation to support? Choose “other” Enter: James Gregoire Scholarship Fund CONTACTS X - @AlwaysOnEM; @VenkBellamkonda; @Marysia_Tweet; @SharonneHayes YouTube - @AlwaysOnEM; @VenkBellamkonda Instagram – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch; @SharonneHayes Email - AlwaysOnEM@gmail.com DO YOU HAVE SCAD? DOES YOUR PATIENT HAVE SCAD? WANT TO GET CONNECTED? SCAD Research: www.scadresearch.org National Coalition for Women with Heart Disease: www.womenheart.org Mayo Clinic Womens Heart clinic: https://www.mayoclinic.org/departments-centers/womens-heart-clinic/overview/ovc-20442061 REFERENCES & LINKS Saleh G, Al-Abcha A, Chaaban K, Adi MZ, Tweet M, Collins JD, Alkhouli M, Gulati R. Concomitant Takotsubo Cardiomyopathy and Spontaneous Coronary Artery Dissection: Exploring the Role of Cardiac Mechanics on Coronary Disruption. JACC Cardiovasc Imaging. 2025 Oct;18(10):1161-1166. doi: 10.1016/j.jcmg.2025.05.020. Epub 2025 Aug 5. PMID: 40758075. Baqal O, Karikalan SA, Hasabo EA, Tareen H, Futela P, Qasba RK, Shafqat A, Qasba RK, Hayes SN, Tweet MS, El Masry HZ, Lee KS, Shen WK, Sorajja D. In- hospital and long-term outcomes in spontaneous coronary artery dissection with concurrent cardiac arrest: Systematic review and meta-analysis. Heart Rhythm O2. 2025 Apr 24;6(6):843-853. doi: 10.1016/j.hroo.2025.03.023. PMID: 40717849; PMCID: PMC12287955. Morosato M, Gaspardone C, Romagnolo D, Pagnesi M, Baldetti L, Dormio S, Federico F, Scandroglio AM, Chieffo A, Godino C, Margonato A, Adamo M, Metra M, Tchetche D, Dumonteil N, Tweet MS, Saw J, Beneduce A. Left Main Spontaneous Coronary Artery Dissection: Clinical Features, Management, and Outcomes. JACC Cardiovasc Interv. 2025 Apr 28;18(8):975-983. doi: 10.1016/j.jcin.2025.01.427. Epub 2025 Apr 9. PMID: 40208153; PMCID: PMC12290918. Tweet MS, Pellikka PA, Gulati R, Gochanour BR, Barrett-O'Keefe Z, Raphael CE, Best PJM, Hayes SN. Coronary Artery Tortuosity and Spontaneous Coronary Artery Dissection: Association With Echocardiography and Global Longitudinal Strain, Fibromuscular Dysplasia, and Outcomes. J Am Soc Echocardiogr. 2024 May;37(5):518-529. doi: 10.1016/j.echo.2024.02.013. Epub 2024 Mar 11. PMID: 38467311; PMCID: PMC11605948. Tweet MS, Hayes SN, Grimaldo ABG, Rose CH. Pregnancy After Spontaneous Coronary Artery Dissection: Counseling Patients Who Intend Future Pregnancy. JACC Adv. 2023 Dec;2(10):100714. doi: 10.1016/j.jacadv.2023.100714. Epub 2023 Nov 14. PMID: 38915307; PMCID: PMC11194843. Tarabochia AD, Tan NY, Lewis BR, Slusser JP, Hayes SN, Best PJM, Gulati R, Deshmukh AJ, Tweet MS. Association of Spontaneous Coronary Artery Dissection With Atrial Arrhythmias. Am J Cardiol. 2023 Jan 1;186:203-208. doi: 10.1016/j.amjcard.2022.09.032. Epub 2022 Oct 31. PMID: 36328832; PMCID: PMC10403149. Murugiah K, Chen L, Dreyer RP, Bouras G, Safdar B, Lu Y, Spatz ES, Gupta A, Khera R, Ng VG, Bueno H, Tweet MS, Spertus JA, Hayes SN, Lansky A, Krumholz HM. Depression and Perceived Stress After Spontaneous Coronary Artery Dissection and Comparison With Other Acute Myocardial Infarction (the VIRGO Experience). Am J Cardiol. 2022 Jun 15;173:33-38. doi: 10.1016/j.amjcard.2022.03.005. Epub 2022 Mar 29. PMID: 35365290; PMCID: PMC9133198. Johnson AK, Tweet MS, Rouleau SG, Sadosty AT, Hayes SN, Raukar NP. The presentation of spontaneous coronary artery dissection in the emergency department: Signs and symptoms in an unsuspecting population. Acad Emerg Med. 2022 Apr;29(4):423-428. doi: 10.1111/acem.14426. Epub 2021 Dec 26. PMID: 34897898; PMCID: PMC10403148. Murugiah K, Chen L, Dreyer RP, Bouras G, Safdar B, Khera R, Lu Y, Spatz ES, Ng VG, Gupta A, Bueno H, Tweet MS, Spertus JA, Hayes SN, Lansky A, Krumholz HM. Health status outcomes after spontaneous coronary artery dissection and comparison with other acute myocardial infarction: The VIRGO experience. PLoS One. 2022 Mar 23;17(3):e0265624. doi: 10.1371/journal.pone.0265624. PMID: 35320296; PMCID: PMC8942215. Adlam D, Tweet MS, Gulati R, Kotecha D, Rao P, Moss AJ, Hayes SN. Spontaneous Coronary Artery Dissection: Pitfalls of Angiographic Diagnosis and an Approach to Ambiguous Cases. JACC Cardiovasc Interv. 2021 Aug 23;14(16):1743-1756. doi: 10.1016/j.jcin.2021.06.027. PMID: 34412792; PMCID: PMC8383825. Kok SN, Tweet MS. Recurrent spontaneous coronary artery dissection. Expert Rev Cardiovasc Ther. 2021 Mar;19(3):201-210. doi: 10.1080/14779072.2021.1877538. Epub 2021 Feb 26. PMID: 33455483. Campbell KH, Tweet MS. Coronary Disease in Pregnancy: Myocardial Infarction and Spontaneous Coronary Artery Dissection. Clin Obstet Gynecol. 2020 Dec;63(4):852-867. doi: 10.1097/GRF.0000000000000558. PMID: 32701519; PMCID: PMC10767871. Tweet MS, Young KA, Best PJM, Hyun M, Gulati R, Rose CH, Hayes SN. Association of Pregnancy With Recurrence of Spontaneous Coronary Artery Dissection Among Women With Prior Coronary Artery Dissection. JAMA Netw Open. 2020 Sep 1;3(9):e2018170. doi: 10.1001/jamanetworkopen.2020. PMID: 32965500; PMCID: PMC7512056. Hayes SN, Tweet MS, Adlam D, Kim ESH, Gulati R, Price JE, Rose CH. Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Aug 25;76(8):961-984. doi: 10.1016/j.jacc.2020.05.084. PMID: 32819471. Johnson AK, Hayes SN, Sawchuk C, Johnson MP, Best PJ, Gulati R, Tweet MS. Analysis of Posttraumatic Stress Disorder, Depression, Anxiety, and Resiliency Within the Unique Population of Spontaneous Coronary Artery Dissection Survivors. J Am Heart Assoc. 2020 May 5;9(9):e014372. doi: 10.1161/JAHA.119.014372. Epub 2020 Apr 28. PMID: 32342736; PMCID: PMC7428589. Tweet MS, Akhtar NJ, Hayes SN, Best PJ, Gulati R, Araoz PA. Spontaneous coronary artery dissection: Acute findings on coronary computed tomography angiography. Eur Heart J Acute Cardiovasc Care. 2019 Aug;8(5):467-475. doi: 10.1177/2048872617753799. Epub 2018 Jan 29. PMID: 29376398; PMCID: PMC6027604. Tan NY, Tweet MS. Spontaneous coronary artery dissection: etiology and recurrence. Expert Rev Cardiovasc Ther. 2019 Jul;17(7):497-510. doi: 10.1080/14779072.2019.1635011. Epub 2019 Jul 5. PMID: 31232618. Waterbury TM, Tweet MS, Hayes SN, Eleid MF, Bell MR, Lerman A, Singh M, Best PJM, Lewis BR, Rihal CS, Gersh BJ, Gulati R. Early Natural History of Spontaneous Coronary Artery Dissection. Circ Cardiovasc Interv. 2018 Sep;11(9):e006772. doi: 10.1161/CIRCINTERVENTIONS.118. PMID: 30354594. Hayes SN, Kim ESH, Saw J, Adlam D, Arslanian-Engoren C, Economy KE, Ganesh SK, Gulati R, Lindsay ME, Mieres JH, Naderi S, Shah S, Thaler DE, Tweet MS, Wood MJ; American Heart Association Council on Peripheral Vascular Disease; Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision Medicine; and Stroke Council. Spontaneous Coronary Artery Dissection: Current State of the Science: A Scientific Statement From the American Heart Association. Circulation. 2018 May 8;137(19):e523-e557. doi: 10.1161/CIR.0000000000000564. Epub 2018 Feb 22. PMID: 29472380; PMCID: PMC5957087. Tweet MS, Kok SN, Hayes SN. Spontaneous coronary artery dissection in women: What is known and what is yet to be understood. Clin Cardiol. 2018 Feb;41(2):203-210. doi: 10.1002/clc.22909. Epub 2018 Mar 1. PMID: 29493808; PMCID: PMC5953427. Tweet MS, Codsi E, Best PJM, Gulati R, Rose CH, Hayes SN. Menstrual Chest Pain in Women With History of Spontaneous Coronary Artery Dissection. J Am Coll Cardiol. 2017 Oct 31;70(18):2308-2309. doi: 10.1016/j.jacc.2017.08.071. PMID: 29073960; PMCID: PMC5957076. Lindor RA, Tweet MS, Goyal KA, Lohse CM, Gulati R, Hayes SN, Sadosty AT. Emergency Department Presentation of Patients with Spontaneous Coronary Artery Dissection. J Emerg Med. 2017 Mar;52(3):286-291. doi: 10.1016/j.jemermed.2016.09. Epub 2016 Oct 8. PMID: 27727035. Tweet MS, Gulati R, Williamson EE, Vrtiska TJ, Hayes SN. Multimodality Imaging for Spontaneous Coronary Artery Dissection in Women. JACC Cardiovasc Imaging. 2016 Apr;9(4):436-50. doi: 10.1016/j.jcmg.2016.01.009. PMID: 27056163. Tweet MS, Gulati R, Hayes SN. What Clinicians Should Know Αbout Spontaneous Coronary Artery Dissection. Mayo Clin Proc. 2015 Aug;90(8):1125-30. doi: 10.1016/j.mayocp.2015.05.010. PMID: 26250728. Prasad M, Tweet MS, Hayes SN, Leng S, Liang JJ, Eleid MF, Gulati R, Vrtiska TJ. Prevalence of extracoronary vascular abnormalities and fibromuscular dysplasia in patients with spontaneous coronary artery dissection. Am J Cardiol. 2015 Jun 15;115(12):1672-7. doi: 10.1016/j.amjcard.2015.03.011. Epub 2015 Mar 23. PMID: 25929580. Goel K, Tweet M, Olson TM, Maleszewski JJ, Gulati R, Hayes SN. Familial spontaneous coronary artery dissection: evidence for genetic susceptibility. JAMA Intern Med. 2015 May;175(5):821-6. doi: 10.1001/jamainternmed.2014. PMID: 25798899. Liang JJ, Prasad M, Tweet MS, Hayes SN, Gulati R, Breen JF, Leng S, Vrtiska TJ. A novel application of CT angiography to detect extracoronary vascular abnormalities in patients with spontaneous coronary artery dissection. J Cardiovasc Comput Tomogr. 2014 May-Jun;8(3):189-97. doi: 10.1016/j.jcct.2014.02.001. Epub 2014 Apr 4. PMID: 24939067. Tweet MS, Hayes SN, Pitta SR, Simari RD, Lerman A, Lennon RJ, Gersh BJ, Khambatta S, Best PJ, Rihal CS, Gulati R. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012 Jul 31;126(5):579-88. doi: 10.1161/CIRCULATIONAHA.112. Epub 2012 Jul 16. PMID: 22800851. Tweet MS, Gulati R, Aase LA, Hayes SN. Spontaneous coronary artery dissection: a disease-specific, social networking community-initiated study. Mayo Clin Proc. 2011 Sep;86(9):845-50. doi: 10.4065/mcp.2011.0312. PMID: 21878595; PMCID: PMC3257995. WANT TO WORK AT MAYO? EM Physicians: https://jobs.mayoclinic.org/emergencymedicine EM NP PAs: https://jobs.mayoclinic.org/em-nppa-jobs Nursing/Techs/PAC: https://jobs.mayoclinic.org/Nursing-Emergency-Medicine EMTs/Paramedics: https://jobs.mayoclinic.org/ambulanceservice All groups above combined into one link: https://jobs.mayoclinic.org/EM-Jobs
Recent research has revealed that the heart health benefits of the weight loss drug Ozempic, which contains the active ingredient semaglutide, are not solely due to weight loss. A large study published in The Lancet and led by researchers at University College London analyzed data from more than seventeen thousand adults aged forty five and older who were overweight and had cardiovascular disease. The participants were randomly assigned to receive weekly injections of semaglutide or a placebo. The study found that semaglutide significantly reduced the risk of major cardiac events such as heart attacks, strokes, and cardiovascular deaths, regardless of how much weight each participant lost during the first four and a half months of treatment. This means that even people who lost little or no weight experienced similar heart protection as those who lost a substantial amount.The study also looked at the impact of waist circumference, which is a marker for visceral fat, and found that a reduction in waist size was linked to about one third of the heart benefits seen in patients taking semaglutide. However, the majority of the cardiovascular benefit was not explained by changes in weight or waist size alone. This suggests that semaglutide may have direct effects on the underlying causes of heart disease, beyond just helping people lose weight. Experts say this could mean the drug might be beneficial for patients who are not severely overweight, including those with BMIs in the normal range, although further research is needed to confirm this.Oprah Winfrey has recently spoken about her own experience with Ozempic, describing it as a tool she uses to manage her weight. She has emphasized that medication is not the only way to lose weight and that it should be seen as one option among many. Oprah has also discussed the broader cultural conversation around weight loss drugs, highlighting the need to address weight stigma and body shaming. Her openness has sparked a national dialogue about the role of prescription medications in weight management and the importance of focusing on overall health rather than just appearance.The findings from the latest research are prompting doctors and researchers to reconsider how they approach the treatment of obesity and heart disease. While Ozempic and similar drugs were originally developed for diabetes, their ability to protect the heart even without significant weight loss is a major development. This could lead to new treatment strategies for people at high risk of cardiovascular events, regardless of their body size. As the medical community continues to explore the full range of benefits and risks associated with these medications, the conversation around weight loss and heart health is becoming more nuanced and inclusive.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI
This week we review the results of the new pivotal trial of the 'Minima' stent by Renata Medical. What is special about this new device that makes it particularly desirable for use in small children? How strong is cobalt chromium and what evidence exists that it can be expanded repeatedly over 1-2 decades? Can this technology supplant surgery for certain diseases such as native coarctation? What are the limitations of this device? We speak with the first author of the pivotal trial, Dr. Patrick Sullivan of CHLA who is Associate Professor of Pediatrics at Keck Medicine at USC. DOI: 10.1161/CIRCINTERVENTIONS.125.015618
Aaysha Cader, MD MSc, social media editor for JACC: Cardiovascular interventions and Josep Rodés-Cabau, MD, PhD discuss the Impact of Early Hemodynamic Valve Deterioration on Long-term Outcomes Following Transcatheter Aortic Valve Replacement, published in the October 27 issue of the journal.
Aaysha Cader, MD MSc, social media editor for JACC: Cardiovascular interventions and Christoph Ryffel, MD discuss the Long-term Outcomes of Patients with Moderate and Severe Aortic Stenosis According to Stages of Cardiac Damage, manucript published in the October 27 issue of the journal.
Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and Jasmine Marquard discuss a recently published study examining PCI in multivessel disease during infarct-related cardiogenic shock.
This episode features Vinay Badhwar, MD, FACS, FACC, Executive Chair of the WVU Heart & Vascular Institute and Gordon F. Murray Professor and Chair of the Department of Cardiovascular & Thoracic Surgery at West Virginia University School of Medicine. Dr. Badhwar discusses the importance of a strong organizational structure, shares insights into the innovative developments his team has been working on, reflects on the values that guide him as a leader, and much more.
Your patient's diagnosed condition is often just one piece of a larger puzzle. Uncover the hidden links between heart, kidney, and metabolic disease to improve care. Credit available for this activity expires: 10/27/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003006?ecd=bdc_podcast_libsyn_mscpedu
Abdullah Al-Abcha, MD, social media editor of JACC: Cardiovascular Interventions, and Robert Herman, MD, PhD discuss AI-Enabled ECG Analysis Improves Diagnostic Accuracy and Reduces False STEMI Activations: A Multicenter U.S. Registry, presented as a Late Breaking Clinical Trial at TCT 2025.
Beyond visible weight gain, hidden fat can build up in organs and muscles, quietly influencing long-term health A recent study published in the European Heart Journal found that where fat collects in your body is closely tied to how quickly your cardiovascular system ages The study showed that visceral fat, liver fat, and fat infiltrating muscles were strongly linked with premature cardiovascular aging Researchers also uncovered gender-specific patterns. Men tended to accumulate more visceral and abdominal fat, while women carried more subcutaneous and thigh fat To protect your heart, shift from focusing only on weight loss to improving metabolic health. Check your metabolic markers, eat the right carbs, cut seed oils, and build strength through daily movement
In this essential episode of Parallax, Dr Ankur Kalra welcomes Dr Monica Tincopa, Assistant Professor of Medicine at the University of California San Diego, for a crucial conversation about Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its profound implications for cardiovascular care. Dr Tincopa guides listeners through the recent transformation from NAFLD to MASLD, explaining why this nomenclature change represents more than just terminology, instead reflecting a deeper understanding of metabolic health that directly impacts cardiology practice. The conversation explores practical screening strategies that cardiologists can implement immediately, including the use of FIB-4 risk stratification and recognizing incidental findings on cardiac imaging. Dr Tincopa shares insights on when to refer patients to hepatology specialists and how the shared risk factors between MASLD and cardiovascular disease create opportunities for comprehensive patient care. This episode equips cardiologists with essential knowledge to identify at-risk patients within their existing practice, understand the cardiovascular implications of liver disease, and optimize care coordination for patients with overlapping metabolic conditions. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.
In this episode, we review the high-yield topic of Cardiac Tamponade from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Coarctation of the Aorta from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
The Real Truth About Health Free 17 Day Live Online Conference Podcast
Joel K. Kahn, M.D., and Kim Williams, M.D., discuss groundbreaking evidence on how adopting a whole food, plant-based diet combined with positive lifestyle changes can drastically improve cardiovascular health. Discover practical steps for a healthier heart and longer life. #HeartHealth #PlantBasedDiet #CardiovascularWellness
This week we review a recent survey study assessing the beliefs of fetal cardiologists and how these may influence the content and conduct of their counseling. Do most fetal cardiologists review all options including intervention, comfort care and pregnancy termination? Should there be a mandate that all do? Is it realistic or appropriate to ask a fetal cardiologist to suggest an option when they do not believe it to be a reasonable or correct choice? We speak with two of the authors of this work and they are Dr. Joanne Chiu of Harvard University and Dr. Caitlin Haxel of The University of Vermont. DOI: 10.1002/pd.6706
In this episode, we review the high-yield topic of Rheumatic Heart Disease from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Did you know that congenital heart defects (CHDs) affect nearly 40,000 babies born in the United States every year? On this episode, Pediatric Cardiologist Dr. Melissa Lefebvre and medical student Marina Hashim discuss the evaluation and management of common acyanotic congenital heart conditions. Specifically, they will: Review the classification of CHDs as cyanotic versus acyanotic. Discuss the pathophysiology of the three most common acyanotic CHDs – ASD, PDA, and VSD. Describe early clinical findings and use of diagnostic tools. Cover management options, ranging from spontaneous closure to surgical intervention. Explore prognosis and long-term outcomes on physical activity, neurodevelopment, and overall health. Special thanks to Dr. Rebecca Yang and Dr. Abeer Hamdy for peer reviewing this episode. CME available free with sign up: Link Coming Soon! References: Dimopoulos, K., Constantine, A., Clift, P., & Condliffe, R. (2023). Cardiovascular complications of down syndrome: Scoping review and expert consensus. Circulation, 147(5). https://doi.org/10.1161/CIRCULATIONAHA.122.059706 Dugdale, D. C. (Ed.). (n.d.). Pediatric heart surgery - discharge. Mount Sinai. Retrieved April 26, 2024, from https://www.mountsinai.org/health-library/discharge-instructions/pediatric-heart-surgery-discharge Eckerström, F., Nyboe, C., Maagaard, M., Redington, A., & Hjortdal, V. (2023). Survival of patients with congenital ventricular septal defect. European Heart Journal, 44 (1,1), 54-61. https://doi.org/10.1093/eurheartj/ehac618 Heart MRI. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21961-heart-mri Leihao, S., Yajiao, L., Yunwu, Z., Yusha, T., Yucheng, C., & Lei, C. (2023). Heart-brain axis: Association of congenital heart abnormality and brain diseases. Frontiers in Cardiovascular Medicine, 10. https://doi.org/10.3389/fcvm.2023.1071820 Meyer, K. (Ed.). (2022, May 1). What is a ventricular septal defect (VSD)? Cincinnati Children's. Retrieved March 12, 2024, from https://www.cincinnatichildrens.org/health/v/vsd Minette, M. S., & Sahn, D. S. (2006). Ventricular septal defects. Circulation, 114(20). https://doi.org/10.1161/CIRCULATIONAHA.106.618124 Mussatto, K. A., Hoffmann, R. G., Hoffman, G. M., Tweddell, J. S., Bear, L., Cao, Y., & Brosig, C. (2014). Risk and prevalence of developmental delay in young children with congenital heart disease. Pediatrics, 133(3), e570–e577. https://doi.org/10.1542/peds.2013-2309 Pruthi, S. (Ed.). (2022, October 21). Ventricular septal defect (VSD). Mayo Clinic. Retrieved April 9, 2024, from https://www.mayoclinic.org/diseases-conditions/ventricular-septal-defect/symptoms-causes/syc-20353495 Right heart catheterization. (2022, July 24). Cleveland Clinic. Retrieved April 19, 2024, from https://my.clevelandclinic.org/health/diagnostics/21045-right-heart-catheterization Shah, S., Mohanty, S., Karande, T., Maheshwari, S., Kulkarni, S., & Saxena, A. (2022). Guidelines for physical activity in children with heart disease. Annals of pediatric cardiology, 15(5-6), 467–488. https://doi.org/10.4103/apc.apc_73_22 Sigmon, E., Kellman, M., Susi, A., Nylund, C., & Oster, M. (2019). Congenital heart disease and Autism: A case-control study. Pediatrics, 144(5). https://doi.org/10.1542/peds.2018-4114 Thacker, D. (Ed.). (2022, January 1). Ventricular septal defect (VSD). Nemours Kids Health. Retrieved April 10, 2024, from https://kidshealth.org/en/parents/vsd.html Tierney, S., & Seda, E. (2020). The benefit of exercise in children with congenital heart disease. Current Opinion in Pediatrics, 32(5), 626-632. https://doi.org/10.1097/MOP.0000000000000942 Ventricular septal defects (VSD). (2021, November 9). Cleveland Clinic. Retrieved April 2, 2024,from https://my.clevelandclinic.org/health/diseases/17615-ventricular-septal-defects-vsd Ventricular septal defect surgery for children. (n.d.). Johns Hopkins Medicine. Retrieved April 11,2024, from https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/ventricular-septal-defect-surgery-for-children#:~:text=During%20this%20surgery%2C%20a%20surgeon,the%20hole%20between%20the%20ventricles Wernovsky, G., & Licht, D. J. (2016). Neurodevelopmental Outcomes in children with congenital heart disease - what can we impact?. Pediatric Critical Care Medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 17(8 Suppl 1), S232–S242. https://doi.org/10.1097/PCC.0000000000000800
In this episode, we review the high-yield topic of Ventricular Septal Defects from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Healthspan isn't just built in the gym — it's shaped by the choices you make all day long. Cardiovascular exercise physiologist Dr. Jim Walter shares how his father's early passing drove his mission to help people extend their healthspan through simple, science-backed daily movements. He explains why the “150 minutes per week” guideline often discourages beginners, introduces his “Move More” approach for adding activity into ordinary tasks, and reveals research showing how even 2,000 extra steps or standing breaks can reduce disease risk and improve brain health. This empowering conversation reframes movement as the most accessible medicine for living longer and better.The information presented in Fully Alive is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before making changes to your health regimen. Guests' opinions are their own and do not necessarily reflect those of the podcast host, production team, or sponsors.Love the show? Subscribe, rate, review, & share! https://www.shellpoint.org/podcast/
On today's Good Day Health Show - ON DEMAND…As the popularity of GLP-1 medications for weight loss and diabetes continues to soar, a dangerous new trend is putting patients at risk: compounded and counterfeit versions flooding the market.In this important episode, Doug Stephan is joined by Leigh Verbois, PharmD, JD, FAPhA — board member of the Alliance for Safe Online Pharmacies (ASOP Global) and former FDA official — to uncover the truth about these unapproved and unsafe products.Verbois shares her insider perspective on:• Why compounded GLP-1s can be hazardous to your health• How deceptive online marketing is driving their rapid spread• What patients, providers, and policymakers can do to stay safeWith years of experience leading the FDA's Office of Drug Security, Integrity, and Response, Leigh Verbois brings vital insights on protecting yourself from unverified medications and ensuring your treatments meet federal safety standards.
In this episode, we review the high-yield topic of Antianginal Therapy from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Mehlman Qbanks: https://qbanks.mehlmanmedical.com/IG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/
En este episodio aclaramos la relación entre el colesterol presente en los alimentos y la salud cardiovascular. Te cuento cómo opino que debe ser una alimentación equilibrada, si debemos eliminar algunos grupos de alimentos y qué otros factores son determinantes.Recibe la newsletter: https://www.lifters.es
Can your cardiovascular exercise really improve your gut health? If so, how? In this episode I discuss new research that shows promising information about endurance exercise and gut health.
In this episode, we review the high-yield topic of Heart Murmurs from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this special series on The Cardiovascular Outcome Trials our host, Dr. Neil Skolnik will discuss the history and importance of the Cardiovascular Outcome Trials for diabetes medications . In Part 1 we discuss an historical perspective with Dr. Steven Nissan and how this has lead to the CVOTs that change the way we practice from EMPA-REG in 2015 to SURPASS-CVOT in 2025. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Steven Nissen, M.D., Chief Academic Officer of the Heart and Vascular Institute at the Cleveland Clinic and Professor of Medicine at the Clevland Clinic Lerner College of Medicine. Selected references: Nissen SE, Wolski K, Topol EJ. Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. JAMA. 2005;294:2581-2586 Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy (ADOPT). N Engl J Med 2006;355:242743. DREAM trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096 Nissen SE, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007;356:2457-2471.
Cardiovascular care is entering one of its most transformative periods in decades. Advances in AI imaging and minimally invasive procedures are transforming the diagnosis and treatment of heart disease. According to the World Health Organization, an estimated 19.8 million people died from cardiovascular diseases in 2022, representing approximately 32% of all global deaths. This makes early detection, innovation, and prevention critical. New technologies promise faster procedures and better outcomes. However, the challenge is to ensure that access, affordability, and quality keep pace with innovation.As technology redefines what's possible in cardiovascular medicine, how can health systems balance innovation with sustainability and make excellence more than just a marketing term?In this episode of I Don't Care, host Dr. Kevin Stevenson reconnects with longtime colleague Jorge Parodi, a cardiovascular service-line leader with experience across major hospitals and health systems. Together, they trace the evolution of cardiovascular care from the rise of service-line models to the latest AI-driven tools shaping diagnosis and treatment. They also unpack what “centers of excellence” really mean today.Key Points of Conversation:From Service Lines to Systems Thinking: How hospitals began aligning cardiovascular services around the patient journey and cutting across departments to improve coordination, quality, and outcomes.Technology at the Heart of Care: Advances like pulse field ablation, AI-assisted CT imaging, and next-generation diagnostic tools are revolutionizing early detection and treatment while reducing invasiveness.Redefining Excellence: Why “center of excellence” designations vary widely across payers and regulators, and how data-driven quality metrics are reshaping what true cardiac leadership looks like.Jorge Parodi is a senior healthcare executive with over two decades of leadership in cardiovascular service line management and hospital operations. He has directed major heart and vascular programs across leading health systems, focusing on strategy, innovation, and quality improvement. Parodi specializes in developing high-performing, technology-driven cardiovascular programs that enhance patient outcomes and operational efficiency.
In patients with heart failure, remote hemodynamic monitoring can identify health changes long before symptoms appear, contributing to slower disease progression, improved patient outcomes, and reduced rehospitalizations. Learn more about current and future technology that can support better patient health, and the role of nurses in patient education and monitoring. Guests: Linda Park, PhD, MS, FNP-BC, FAAN, FAHA, FPCNA, and Eryn Bryant, MSN, APRN-CNP, FPCNA.PCNA Heart Failure Tools: https://pcna.net/health-topics/heart-failure/Tele-HF study: https://www.jacc.org/doi/10.1016/j.jchf.2015.07.017 CHAMPION Trial (CMEMs after CRT): Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction https://www.acc.org/latest-in-cardiology/clinical-trials/2015/12/29/12/44/championJournal of American College of Cardiology paper, Remote Monitoring and Heart Failure Scientific Statement: https://www.jacc.org/doi/10.1016/j.jacc.2023.04.010 European Society of Cardiology consensus statement: https://doi.org/10.1093/eurheartjsupp/suae116BMAD trial: BMAD Trial: Wearable Remote Monitor Reduces Hospital Readmission Risk in HF Patients - American College of Cardiology: https://www.acc.org/Latest-in-Cardiology/Articles/2023/03/01/22/45/mon-830am-bmad-acc-2023 GUIDE-HF trial (CMEMS, Lancet): Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial - The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01754-2/abstractESCAPE trial (using RHC / pulm art pressures to guide therapy during ADHF: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial - PubMed: https://pubmed.ncbi.nlm.nih.gov/16204662/MONITOR-HF trial (improved QOL and functional status w/ CMEMs): Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial - The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00923-6/abstract MONITOR-HF: Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial | European Heart Journal | Oxford Academic: https://academic.oup.com/eurheartj/article/45/32/2954/7668040MONITOR-HF (summary in ACC): Remote Hemodynamic Monitoring of Pulmonary Artery Pressures in Patients With Chronic Heart Failure - American College of Cardiology: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/07/18/17/21/monitor-hfHeartLogic: HeartLogic Multisensor Algorithm Identifies Patients During Periods of Significantly Increased Risk of Heart Failure Events: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.117.004669SCALE-HF-1 Trial (bodyport scale to predict worsening HF trends): Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1 | Circulation: Heart Failure: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.122.010012See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, we review the high-yield topic of Lipid Lowering Drugs from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
With Jean-Benoit Le Polain de Waroux, St-Jan Hospital, Brugge - Belgium, and Maarten De Smet, AZ Sint Jan, Brugge - Belgium. Link to European Heart Journal paper Link to European Heart Journal editorial
In this episode, we review the high-yield topic of Large Vessel Vasculitides from the Cardiovascular section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
This week we review an episode from 3 years back and delve into the world of adult congenital heart disease when we review a recent work from the ACHD team at UCSF that assesses the impact of BMI on clinical outcomes in the single ventricle adult Fontan patient. What is the cause of elevation in BMI in some Fontan patients? Is obesity the only explanation? Is BMI a modifiable risk factor for our Fontan patients and should exercise be 'prescribed' for these patients? If so prescribed, what type of exercise is best for the Fontan patient? This week's work's senior author, Dr. Anushree Agarwal, Assistant Professor of Medicine at UCSF, shares her insights into this important topic. DOI: 10.1161/JAHA.122.026732Also mentioned in today's episode is episode #222 with Dr. Dan Halpern of NYU medical center (https://www.stitcher.com/show/pediheartpediatric-cardiology-today/episode/pediheart-podcast-222-impact-of-cardiac-rehab-on-exercise-tolerance-in-the-achd-patient-206781483)
Dr. Gregg Day and Drs. Laura Baker and Melissa Yu discuss interventions that enhance or safeguard cognitive function in older adults at risk of cognitive decline and dementia. Show reference: https://jamanetwork.com/journals/jama/article-abstract/2837046
Associate Professor Jodie Ingles leads Australia’s National Registry for Genetic Heart Disease, bringing together patients and families to improve diagnosis, treatment and understanding of inherited heart conditions through cutting-edge genomic research. Prof. Ingles and her team at the Garvan Institute are researching the genetic causes of inherited heart diseases, such as cardiomyopathies and arrhythmias, which can lead to sudden cardiac death. Their work focuses on identifying the underlying genetic mutations that put individuals and families at risk, using advanced genomic sequencing and data from the National Registry for Genetic Heart Disease. By combining genetic insights with clinical information, they aim to improve diagnosis, guide personalised treatment, and inform family screening. The team also studies how families experience and respond to genetic testing, helping to shape better care and counselling for affected Australians.See omnystudio.com/listener for privacy information.
Dr. Gregg Day talks with Drs. Laura Baker and Melissa Yu about the impact of lifestyle interventions on cognitive function in older adults. Read the related article in JAMA. Disclosures can be found at Neurology.org.
This week we review a recent work from the "Women In Pediatric Cardiology" group which is a 4 year old initiative to help lift up women pediatric cardiologists through the fostering of connections and also via mentorship programs. Why did this program develop and what are the most pressing issues affecting female pediatric cardiologists? What are the best solutions to help address gender inequities in our field? We speak with two co-authors of this week's work, Drs. Sarah Ford of Brown University and Kristin Laraja of University of Massachussetts. For those interested in participating in their work, feel free to email Pediheart@gmail.com and your information will be passed along to the authors. DOI: 10.1007/s00246-024-03576-9
This podcast is sponsored by YARAL Pharma. In this episode, we are focusing on the management of hypothyroidism -- a treatable, but not curable condition – and will explore unique challenges for patients with hypothyroidism in long-term care – from tolerability and formulation considerations to consistent dosing and patient needs. Dr. Tamara Ruggles is not affiliated with YARAL Pharma. All views and opinions regarding hypothyroidism are solely her own and are not attributable to YARAL or the Pharmacy Podcast Network. IMPORTANT SAFETY INFORMATION for levothyroxine sodium capsules INDICATION AND USAGE Levothyroxine sodium capsules are L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer Limitations of Use: Levothyroxine sodium capsules are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine sodium capsules may induce hyperthyroidism. Levothyroxine sodium capsules are not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis WARNING: NOT FOR THE TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium capsules, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. Contraindications Uncorrected adrenal insufficiency Warnings and Precautions Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate Levothyroxine sodium capsules at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of levothyroxine sodium capsules treatment Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone reabsorption and decrease bone mineral density. Give the lowest effective dose Adverse Reactions Common adverse reactions with levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdosage. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central Nervous System: headache, hyperactivity, nervousness, anxiety, irritability, emotional ability, insomnia Musculoskeletal: tremors, muscle weakness Cardiovascular: palpitations, tachycardia, arrythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal (GI): diarrhea, vomiting, abdominal cramps, elevations in liver function tests Dermatologic: hair loss, flushing Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Adverse Reactions in Children Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height. Seizures have been reported rarely with the institution of levothyroxine therapy. Hypersensitivity Reactions Hypersensitivity reactions to inactive ingredients (in this product or other levothyroxine products) have occurred in patients treated with thyroid hormone products. These include urticaria, pruritis, skin rash, flushing, angioedema, various GI symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness and wheezing. Hypersensitivity to levothyroxine itself is not known to occur. Drug Interactions: Many drugs and some foods can exert effects on thyroid hormone pharmacokinetics (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine sodium capsules. Administer at least 4 hours before or after drugs that are known to interfere with absorption. See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism. To report SUSPECTED ADVERSE REACTIONS, contact Yaral Pharma Inc. at 1-866-218-9009, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Full Prescribing Information, including Boxed Warning, go to www.yaralpharma.com/levothyroxine-pi.
In this episode, Dr. Jagmeet Singh of Harvard Medical School and Massachusetts General Hospital and Dr. Sanjay Gandhi of Philips Healthcare Informatics discuss how AI, sensors, and digital tools are reshaping cardiovascular care. They share insights on moving from reactive to proactive care, improving efficiency, and empowering both clinicians and patients in an evolving healthcare landscape.This episode is sponsored by Philips EI.
Cardiovascular disease has been among the leading causes of death in America for decades. It's clear that optimizing the human heart is critical for longevity – but are there really sustainable ways to achieve this? In this episode, Mark Young joins us to discuss how isometric exercise can improve cardiovascular health and overall wellness. Mark Young is a serial entrepreneur, health tech innovator, and marketing expert with a passion for functional fitness. He serves as CEO of Ryze Agency, a Florida-based marketing firm that helps brands grow through strategic storytelling and data-driven marketing. Always eager to inspire action, Mark leads eight high-impact ventures spanning advertising, retail distribution, out-of-home TV networks, real estate development, angel investing, health and fitness, and professional auto racing. Dive in now to discover: The benefits of making non-pharmaceutical decisions. The link between isometrics and blood pressure. How isometric exercise differs from other forms of exercise. What happens when blood flow is increased in the body. Are you ready to take control of your heart health and unlock a stronger, longer-lasting version of yourself? Hit play now! Stay connected with Mark's work by visiting his website or following him on Instagram @themarkyoung. And to learn more about how cardiovascular conditioning is achieved with isometric exercise, www.zona.com should be your first stop! Episode also available on Apple Podcasts: http://apple.co/30PvU9C
Each year, Advisory Board delivers an update on the most significant trends shaping service line strategy – identifying exactly what service line and strategy leaders should prioritize in the year ahead. In this episode, host Rae Woods is joined by Advisory Board experts Lindsey Paul, Kristin Strubel, Gabriela Marmolejos, and Ellie Wiles to unpack the universal challenges specialties are facing as we head into 2026. Throughout the conversation, you'll hear how access constraints, workforce pressures, policy changes, and innovative payment models are influencing key service lines—including oncology, cardiovascular, women's health, and neurology. Looking for insights on a specific service line? Jump ahead using the timestamps below: 1:26 – 6:50: Lindsay Paul on oncology 6:51 – 12:14: Kristen Strubel on cardiovascular 14:08 – 22:29: Gabriela Marmolejos on women's health 22:30 – 27:58: Ellie Wiles on neurology We're here to help: Oncology service line outlook – 2025 Cardiovascular service line outlook – 2025 Women's health service line outlook – 2025 Neurosciences service line outlook – 2025 Orthopedics service line outlook – 2025 Watch our member testimonials and learn about upcoming Advisory Board events Blood-based colorectal screening: A closer look for health plans A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.